Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
March 30, 2020 06:05 ET
|
Cocrystal Pharma, Inc.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 12, 2019 08:35 ET
|
Cocrystal Pharma, Inc.
– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) – –...
Cocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update
November 12, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
May 11, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, May 11, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Achillion Appoints Dr. Frank Verwiel to Board of Directors
December 16, 2015 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive...
Achillion Reports Third Quarter And Nine Month 2015 Financial Results
November 05, 2015 17:51 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the...